Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management will engage in a fireside chat on Tuesday, May 20th at 9:00 am ET. Investors can access the live webcast through Disc Medicine's investor relations website at ir.discmedicine.com, with an archived replay available after the event.
Details
News Market Reaction – IRON
The recorded move for IRON in the trading session of this news was -0.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20th at 9:00 am ET.
A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.